Microbial diversity in the cystic fibrosis airways: where is thy sting?
Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis
First Bacterial Infection as an Alternative Clinical End Point for Regulatory Approval of Agents Targeting the Primary Cystic Fibrosis Defect
How much doPseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients
Trends in the use of routine therapies in cystic fibrosis: 1995-2005
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease
Characterizing aggressiveness and predicting future progression of CF lung disease
Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations
Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis